
Novo Nordisk Egypt promotes new General Manager
pharmafile | September 28, 2017 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Novo Nordisk, biotech, drugs, pharma, pharmaceutical
Novo Nordisk Egypt has promoted Hassan Fahmi to become its new General Manager for operations within the company. Fahmi arrived at the company as a Business Development Manager and rose through the ranks, despite not having any previous knowledge of working within the pharmaceutical industry.
Fahmi arrived at the company with a background mostly in marketing and managing brands for large companies, including Procter & Gamble and Juhayna Food Industries. Prior to this he also had experience within television advertising, film and documentary business, as a producer and marketing manager.
He eventually joined Novo Nordisk as Business Development Manager, before becoming Marketing & MAPA Director for Novo Nordisk Egypt and his eventual appointment to the General Manager position.
On his appointment to the position, Fahmi said “I am proud to be leading a company that creates life changing medications such as Tresiba and Victoza. Tresiba is a once-daily basal insulin injection allowing flexibility in day-to-day dosing time, providing ultra-long diabetes treatment beyond 42 hours, therefore, it is recommended for people with diabetes who are fasting during the month of Ramadan, and those who may miss their insulin dose due to the change of daily lifestyle during fasting.”
Related Content

Amphista doses first patient in AML trial of protein degrader
Amphista Therapeutics has dosed the first patient in a phase 1 trial of AMX-883, an …

Digital platform cuts pharmaceutical quality-record approval times by up to 90%
A digital platform for exchanging pharmaceutical quality records between supply-chain partners is now commercially available, …

Agentic commercial: how AI creates dialogue with HCPs and patients to help medicines reach them faster
By Chris Moore Commercial engagement in biopharma used to centre largely on direct conversations between …






